Last Articles in TAVR in solaci.org

We share the latest works in TAVI published on our website.

Last Articles in TAVR in solaci.org

01- HYDRA CE | New Models for TAVR Development

The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate.  With this study, the Hydra will obtain the CE mark and go after FDA approval (just as all new devices). 

Read more HERE

02- TAVR vs Sutureless Surgical Aortic Valve Replacement in Low-Risk Patients

Sutureless surgical aortic valve replacement (SU-SAVR) has been designed to make surgical valve replacement easier and faster, especially compared against conventional biological valves which require multiple sutures; their rapid deployment translates into reduced cross-clamp and operative time.

Read more HERE

03- TCT 2021 | SURTAVI: Good News for the Self-Expandable Valve at 5 Years

After a 5-year followup, the transcatheter aortic replacement (TAVR) with the self-expandable valve has offered clinical outcomes similar to surgical aortic valve replacement (SAVR) outcomes for intermediate risk patients. 

Read more HERE

04- Is Troponin Elevation After TAVR Related to Mortality?

Troponins have long had diagnostic value not only for infarction. Their ability to predict mortality is well established for all cardiac conditions. Moreover, it has been demonstrated in all critically ill patients, including patients with COVID-19, regardless of the triggering condition.

Read more HERE

05- Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines. 

Read more HERE

06- European Consensus on Antithrombotic Management in TAVR

All the controlled randomized evidence recently published called for an updated document on antithrombotic management in transcatheter aortic valve replacement (TAVR).

Read more HERE

07- Minimizing One of Our Major Procedures to a Minimum

In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR). This highlights the usefulness of extending monitoring after discharge, particularly in patients who tolerated the procedure well, but meet high-risk criteria.

Read more HERE

08- Ten Commandments for 2021 Guidelines on Valvular Heart Disease

Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty of evidence has been accumulating, finally leading to this updated version. 

Read more HERE


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

The El Salvador 2024 Sessions are coming soon

The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Virtual Event SOLACI-Medtronic | The Visible Heart Lab

We invite you to participate in a new virtual activity organized in collaboration with Medtronic, focused on "The Visible Heart Lab" and dedicated to...

SOLACI-CACI 2024 – Presentations day 3

Discover the highlights of the third day of activities of  SOLACI-CACI 2024 Congress, held from August 7 to 9 at the Hilton Hotel in Buenos Aires, Argentina. Dr....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...